Medical AI technologies
DIAGNOS develops AI technologies for medical image analysis and clinical diagnosis support.

Diagnos is a public company applying artificial intelligence to visual health.
diagnosmedical.comCrawled Nov 14, 2026
DIAGNOS develops AI technologies for medical image analysis and clinical diagnosis support.
DIAGNOS uses artificial intelligence to advance healthcare.
DIAGNOS creates AI solutions to enhance clinical analysis and early detection.
DIAGNOS protects user privacy and data confidentiality.
DIAGNOS provides legal notices and site policies.
DIAGNOS expands the rollout of its CARA System across Canada after Health Canada licenses the solution. The deployment follows successful installations in an initial group of optometry clinics, marking a key step in scaling the technology nationwide.
DIAGNOS submits its CARA System to the US FDA as part of its regulatory strategy. The move aims to accelerate the system’s potential approval process for clinical or diagnostic use. CARA integrates advanced imaging and AI-driven analytics for medical diagnostics.
DIAGNOS schedules its annual general meeting of shareholders for **September 30, 2026**. The event will allow shareholders to review company updates and vote on key resolutions. No additional details on agenda items or financial results are provided in the announcement.
DIAGNOS secures a medical device license from the Saudi Food and Drug Authority (SFDA) for its **CARA System**. The approval allows the company to legally market and distribute the diagnostic device in Saudi Arabia. The CARA System is designed for advanced medical imaging and analysis.
DIAGNOS secures a **Health Canada medical device licence** for its **CARA System**, a diagnostic tool. The approval enables the company to legally market and distribute the device in Canada. CARA is designed to support clinical decision-making in healthcare settings.
DIAGNOS is extending the exercise period for its stock warrants. The move allows warrant holders more time to convert their instruments into company shares. This adjustment may impact investor decisions regarding DIAGNOS’s equity instruments.